Sygnis restructures

Sygnis Pharma AG (Xetra:LIO) will restructure and reduce headcount by 19 (37%) to 32 to save cash. Sygnis said it will focus on AX200, an endogenous granulocyte colony-stimulating factor (G-CSF) prote...